230 related articles for article (PubMed ID: 16106597)
1. Hasty approval, more withdrawals.
Prescrire Int; 2005 Aug; 14(78):144. PubMed ID: 16106597
[TBL] [Abstract][Full Text] [Related]
2. When is a medical product too risky? An interview with FDA's top drug official. Interview by Tamar Nordenberg.
Woodcock J
FDA Consum; 1999; 33(5):8-11, 13. PubMed ID: 10522164
[No Abstract] [Full Text] [Related]
3. Canadian and US drug approval times and safety considerations.
Rawson NS; Kaitin KI
Ann Pharmacother; 2003 Oct; 37(10):1403-8. PubMed ID: 14519031
[TBL] [Abstract][Full Text] [Related]
4. Trends in development and approval times for new therapeutics in the United States.
Reichert JM
Nat Rev Drug Discov; 2003 Sep; 2(9):695-702. PubMed ID: 12951576
[TBL] [Abstract][Full Text] [Related]
5. New drugs and product approvals from 2000.
Taylor SE; Gage TW
Tex Dent J; 2001 Nov; 118(11):1070-81. PubMed ID: 11806330
[No Abstract] [Full Text] [Related]
6. Analysis of pharmaceutical safety-related regulatory actions in Japan: do tradeoffs exist between safer drugs and launch delay?
Yamada T; Kusama M; Hirai Y; Arnold F; Sugiyama Y; Ono S
Ann Pharmacother; 2010 Dec; 44(12):1976-85. PubMed ID: 21098757
[TBL] [Abstract][Full Text] [Related]
7. Could conditional release of new drugs provide the information required to study drug effectiveness? - A discussion paper.
Rawson NS; West R; Appel WC
Can J Clin Pharmacol; 2000; 7(4):185-90. PubMed ID: 11118964
[TBL] [Abstract][Full Text] [Related]
8. New drug approval times and 'therapeutic potential' in Canada, Australia, Sweden and the United States during the period 1992 to 1998.
Rawson NS; Kaitin KI
Can J Clin Pharmacol; 2000; 7(2):97-101. PubMed ID: 10958705
[TBL] [Abstract][Full Text] [Related]
9. Statisticians in European regulatory agencies.
Skovlund E
Pharm Stat; 2009; 8(4):259-63. PubMed ID: 19301357
[TBL] [Abstract][Full Text] [Related]
10. Conditional approval and approval under exceptional circumstances as regulatory instruments for stimulating responsible drug innovation in Europe.
Boon WP; Moors EH; Meijer A; Schellekens H
Clin Pharmacol Ther; 2010 Dec; 88(6):848-53. PubMed ID: 20962774
[TBL] [Abstract][Full Text] [Related]
11. The characteristics and fulfillment of conditional prescription drug approvals in Canada.
Law MR
Health Policy; 2014 Jun; 116(2-3):154-61. PubMed ID: 24703857
[TBL] [Abstract][Full Text] [Related]
12. Assessing prescription medications for priority regulatory review.
Rawson NS
Regul Toxicol Pharmacol; 2005 Jun; 42(1):70-6. PubMed ID: 15896445
[TBL] [Abstract][Full Text] [Related]
13. Biopharmaceuticals: recent approvals and likely directions.
Walsh G
Trends Biotechnol; 2005 Nov; 23(11):553-8. PubMed ID: 16051388
[TBL] [Abstract][Full Text] [Related]
14. Curbing industry sponsor's incentive to design post-approval trials that are suboptimal for informing prescribers but more likely than optimal designs to yield favorable results.
Falit BP
Seton Hall Law Rev; 2007; 37(4):969-1049. PubMed ID: 18363220
[No Abstract] [Full Text] [Related]
15. Food and Drug Administration approval process for ophthalmic drugs in the US.
Lloyd R; Harris J; Wadhwa S; Chambers W
Curr Opin Ophthalmol; 2008 May; 19(3):190-4. PubMed ID: 18408492
[TBL] [Abstract][Full Text] [Related]
16. Postmarketing modifications in the safety labeling of the new antiepileptics.
Buck ML; Gurka MJ; Goodkin HP
Neurology; 2007 May; 68(18):1536-7. PubMed ID: 17470758
[No Abstract] [Full Text] [Related]
17. Former pharma pitchman: beware of new drugs. An industry insider advises considering the older options if you need a prescription. Interview by Sarah Baldauf.
Nesi T
US News World Rep; 2008 Nov 3-10; 145(10):64. PubMed ID: 18998444
[No Abstract] [Full Text] [Related]
18. Cardiovascular safety of drugs not intended for cardiovascular use: need for a new conceptual basis for assessment and approval.
Borer JS; Pouleur H; Abadie E; Follath F; Wittes J; Pfeffer MA; Pitt B; Zannad F
Eur Heart J; 2007 Aug; 28(15):1904-9. PubMed ID: 17615083
[TBL] [Abstract][Full Text] [Related]
19. Preventing adverse drug reactions in the general population.
Pezalla E
Manag Care Interface; 2005 Oct; 18(10):49-52. PubMed ID: 16265935
[TBL] [Abstract][Full Text] [Related]
20. Perseverance.
Prescrire Int; 2011 Feb; 20(113):54. PubMed ID: 21488600
[No Abstract] [Full Text] [Related]
[Next] [New Search]
